February 17, 2009Open Access

mTOR Inhibitor RAD001 (Everolimus) Has Antiangiogenic/Vascular Properties Distinct from a VEGFR Tyrosine Kinase Inhibitor

Key Points

Key points are not available for this paper at this time.

Abstract

VEGFR and mTOR inhibitors show similar but also distinct effects on tumor vascular biology, which has implications for their clinical activity alone or in combination.

AI से पूछें

Bookmark

View Full Paper

Cite This Study

Lane et al. (Tue,) studied this question.

synapsesocial.com/papers/69db22f01e19c8ae08836846 https://doi.org/https://doi.org/10.1158/1078-0432.ccr-08-2057

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial2008 · 3,013 citations
2Dosing of rapamycin is critical to achieve an optimal antiangiogenic effect against cancer2004 · 93 citations
3Rapamycin Resistance Tied to Defective Regulation of p27 <i> <sup>Kip1</sup> </i>1996 · 211 citations
4All Roads Lead to mTOR: Integrating Inflammation and Tumor Angiogenesis2007 · 110 citations
5Tumor Recovery by Angiogenic Switch from Sprouting to Intussusceptive Angiogenesis after Treatment with PTK787/ZK222584 or Ionizing Radiation2008 · 134 citations

AI से पूछें

Bookmark

View Full Paper